AnalystBook Research · Company Intelligence

AMERISAFE INC

AMSFNasdaq

Built from AMERISAFE INC's own SEC filings · updates as new filings land · sources cited throughout

or browse all covered companies

AMERISAFE revenue rose 2.7% to $317.3M, net income fell 15.0%, and free cash flow fell to $8.9M.

The read at a glance✓ Audited against SEC data
  • Business mixWorkers' compensation insuranceNote
  • RevenueRevenue rose 2.7% to $317.3MOK
  • ProfitabilityNet income fell 15.0%Watch
  • CashFree cash flow fell 61.8%Watch
  • Balance sheetEquity fell 2.2%Watch
  • Insiders0 buys / 3 sellsWatch
  • AccountingForensic screen unavailableNote

Business

AMERISAFE is a specialty workers' compensation insurer focused on small and mid-sized employers in hazardous industries such as construction, trucking, logging, agriculture, services, manufacturing, and maritime.

Leadership changes

From AMERISAFE INC's own filings, the day they're filed.

  • Guillermo A. Ramos · President · appointmenteff. 2026-05-07
  • G. Janelle Frost · Chief Financial Officer · departureeff. 2025-04-30
  • Andrew McCray · President · departureeff. 2023-10-11

Latest filings

  • 10-Q · Quarterly report2026-07-23
  • 8-K · Company announcement2026-07-21
  • 8-K · Company announcement2026-06-12
  • DEF 14A · Annual proxy (pay & governance)2026-04-24
  • 10-Q · Quarterly report2026-04-23
In the full recordFree for 14 days
  • What changed🔒
  • Insider signal🔒
  • Growth quality🔒
  • Margins & accounting🔒
  • Capital allocation🔒
  • Real risks🔒
  • The long arc🔒
  • Company history🔒
  • Main tension🔒
  • The filings, readable — with what changed vs the prior year highlighted🔒
  • Full financial statements, industry-aware, sources cited throughout🔒
  • Forensic score history & components — the trend, not one year🔒
  • Ownership: insider buys/sells, clusters, activist stakes🔒
  • Ana — ask about AMERISAFE INC, every answer cited to the official filings🔒

Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.

14-day free trial, no credit card. For research purposes only; not investment advice.